Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Reveal LINQ™ Heart Failure (LINQ HF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02758301
Recruitment Status : Completed
First Posted : May 2, 2016
Results First Posted : November 12, 2019
Last Update Posted : November 12, 2019
Sponsor:
Information provided by (Responsible Party):
Medtronic Cardiac Rhythm and Heart Failure

Brief Summary:
The purpose of the LINQ™ HF study is to characterize Reveal LINQ™ derived data from patients with heart failure by assessing the relationship between changes in LINQ™ derived data and other physiologic parameters with subsequent acute decompensated heart failure (ADHF) events.

Condition or disease Intervention/treatment
Heart Failure Device: Reveal LINQ™ Insertable Cardiac Monitor (ICM)

Detailed Description:

The study is a prospective, non-randomized, multi-center, observational, pre-market clinical study. The study is expected to be conducted at up to 30 centers in the United States. Up to 300 subjects will be enrolled to achieve approximately 40 heart failure events (no more than two per subject will contribute to the cumulative total). Study subjects will be followed for up to 3 years post-insertion or until official study closure defined as when Medtronic and/or regulatory requirements have been satisfied per the Clinical Investigation Plan and/or by a decision by Medtronic or regulatory authority, whichever occurs first. The expected study duration is approximately 4 years representing 1.5 years of enrollments and 2.5 years of follow-up.

The LINQ™ HF study is a Non-Significant Risk Investigational Device Exemption (IDE) study. The study is utilizing the Reveal LINQ™ device with an investigational LINQ™ HF RAMware download.

Layout table for study information
Study Type : Observational
Actual Enrollment : 112 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Reveal LINQ™ Heart Failure
Actual Study Start Date : June 8, 2016
Actual Primary Completion Date : December 4, 2018
Actual Study Completion Date : December 4, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure

Group/Cohort Intervention/treatment
Diagnostic
The Reveal LINQ™ Insertable Cardiac Monitor (ICM) device will be inserted in all subjects for continuous monitoring. After the Reveal LINQ™ device is inserted, the LINQ™ HF investigational RAMware will be downloaded to the LINQ™ ICM.
Device: Reveal LINQ™ Insertable Cardiac Monitor (ICM)
Insertable Cardiac Monitor with LINQ™ HF Investigational RAMware download




Primary Outcome Measures :
  1. Number of Participants With Reveal Device Experiencing an Initial Acute Decompensated Heart Failure (ADHF) Event [ Time Frame: 30 days post-Reveal LINQ insertion to 3 years post-implant ]

    A heart failure (HF) event is defined as any cardiovascular-related Health Care Utilizations (HCUs) for any one of the following events.

    • Admission with primary diagnosis of HF
    • Intravenous HF therapy (e.g. IV diuretics/vasodilators) or ultrafiltration at any one of the following settings:

      1. Admission with secondary/tertiary diagnosis of HF
      2. Emergency Department
      3. Ambulance
      4. Observation Unit
      5. Urgent Care
      6. HF/Cardiology Clinic

    Up to 2 ADHF events were intended to be allowed per subject:

    1. One had to be at least 30 days post-Reveal LINQ insertion and is summarized in this section, and
    2. A possible second ADHF event must be greater than 90 days after the first ADHF event

    Only subjects with a LINQ device were included in the analysis, as the goal was to acquire LINQ-collected data leading up to the ADHF event.


  2. Number of Participants With a LINQ Device Experiencing a Second Acute Decompensated Heart Failure (ADHF) Events [ Time Frame: > 90 days following first Acute Decompensated Heart Failure event to 3 years post-implant ]

    A heart failure (HF) event is defined as any cardiovascular-related Health Care Utilizations (HCUs) for any one of the following events.

    • Admission with primary diagnosis of HF
    • Intravenous HF therapy (e.g. IV diuretics/vasodilators) or ultrafiltration at any one of the following settings:

      1. Admission with secondary/tertiary diagnosis of HF
      2. Emergency Department
      3. Ambulance
      4. Observation Unit
      5. Urgent Care
      6. HF/Cardiology Clinic

    Up to two ADHF events per subject were intended to be evaluated. The first must be at least 30 days post-Reveal LINQ insertion, and the second, summarized in this section, must be greater than 90 days following the first ADHF event.

    Only subjects with a LINQ device were included in the analysis, as the goal was to acquire LINQ-collected data leading up to the ADHF event.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The subject population for the LINQ™ HF study is patients with heart failure with a NYHA Class III who meet all of the inclusion and none of the exclusion criteria.
Criteria

Inclusion Criteria:

  • Patient is 18 years of age or older
  • Patient (or patient's legally authorized representative) is willing and able to provide written informed consent
  • Patient is willing and able to comply with the protocol, including follow-up visits and CareLink transmissions
  • Patient is NYHA Class III, per most recent assessment or at any time within 30 days prior to enrollment
  • Patient had a HF event (HF event defined as meeting any one of the following three criteria):

    1. Admission with primary diagnosis of HF within the last 6 months, OR
    2. Intravenous HF therapy (e.g. IV diuretics/vasodilators) or ultrafiltration at any one of the following settings within the last 6 months:

      • Admission with secondary/tertiary diagnosis of HF
      • Emergency Department
      • Ambulance
      • Observation Unit
      • Urgent Care
      • HF/Cardiology Clinic
      • Patient's Home, OR
    3. Patient had the following BNP/NTpro-BNP within the last 3 months: If EF ≥ 50%, then BNP> 200 pg/ml or NTpro-BNP > 400 pg/ml OR If EF <50%, then BNP> 400 pg/ml or NTpro-BNP > 800 pg/ml

Exclusion Criteria:

  • Patient is pregnant (all females of child-bearing potential must have a negative pregnancy test within 1 week of enrollment)
  • Patient is enrolled in another study that could confound the results of this study, without documented pre-approval from a Medtronic study manager
  • Patient has severe valvular heart disease as defined by hemodynamically significant valve stenosis and/or prosthetic heart valve
  • Patient has existing IPG, ICD, CRT-D or CRT-P device
  • Patient has severe renal impairment (eGFR <25mL/min)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02758301


Locations
Show Show 19 study locations
Sponsors and Collaborators
Medtronic Cardiac Rhythm and Heart Failure
  Study Documents (Full-Text)

Documents provided by Medtronic Cardiac Rhythm and Heart Failure:
Layout table for additonal information
Responsible Party: Medtronic Cardiac Rhythm and Heart Failure
ClinicalTrials.gov Identifier: NCT02758301    
Other Study ID Numbers: LINQ HF
First Posted: May 2, 2016    Key Record Dates
Results First Posted: November 12, 2019
Last Update Posted: November 12, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases